We now propose a clinical diagnostic toolkit combining CIP2A and BCL-XL biomarkers to stratify CML patients by the risk of disease progression and likelihood of achieving successful TFR. Here, CIP2A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.